Figure 4. Concentration-response curves to cromakalim and pinacidil in the absence or the presence of mexiletine (10-5, 3 x 10-5, 10-4M) obtained in rat thoracic aortas without endothelia. Data are shown as the mean +/− SD and expressed as percent of maximal relaxation induced by papaverine (3 x 10-4M; 100%= 813 +/− 222 mg [n = 6], 860 +/− 87 mg [n = 6], 787 +/− 126 mg [n = 6], and 773 +/− 213 mg [n = 6] for control rings of cromakalim and rings treated with mexiletine [10-5M], mexiletine [3 x 10-5M], or mexiletine [10-4M]; 100%= 832 +/− 209 mg [n = 5], 776 +/− 96 mg [n = 5], 784 +/− 173 mg [n = 5], and 808 +/− 151 mg [n = 5] for control rings of pinacidil and rings treated with mexiletine [10-5M], mexiletine [3 x 10-5M], or mexiletine [10-4M], respectively). *Difference between control rings and rings treated with mexiletine is statistically significant (P < 0.05).

Figure 4. Concentration-response curves to cromakalim and pinacidil in the absence or the presence of mexiletine (10-5, 3 x 10-5, 10-4M) obtained in rat thoracic aortas without endothelia. Data are shown as the mean +/− SD and expressed as percent of maximal relaxation induced by papaverine (3 x 10-4M; 100%= 813 +/− 222 mg [n = 6], 860 +/− 87 mg [n = 6], 787 +/− 126 mg [n = 6], and 773 +/− 213 mg [n = 6] for control rings of cromakalim and rings treated with mexiletine [10-5M], mexiletine [3 x 10-5M], or mexiletine [10-4M]; 100%= 832 +/− 209 mg [n = 5], 776 +/− 96 mg [n = 5], 784 +/− 173 mg [n = 5], and 808 +/− 151 mg [n = 5] for control rings of pinacidil and rings treated with mexiletine [10-5M], mexiletine [3 x 10-5M], or mexiletine [10-4M], respectively). *Difference between control rings and rings treated with mexiletine is statistically significant (P < 0.05).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal